CVS Health Corporation (CVS)

Market Closed

5 Dec, 20:00

NYSE

75. 63

-1.12

-1.46%

101.38B Market Cap

11.4 P/E Ratio

2.66% Div Yield

5,858,041 Volume

7.87 Eps

$ 76.75

Previous Close

Day Range

74.98 76.86

Year Range

43.56 85.15

Want to track CVS and more in your Portfolio? 🎯

Get Started For Free

Earnings results expected in 67 days

CVS wins upgrade to buy as analyst sees more upside potential than its peers

A Leerink analyst says CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits businesses.

Marketwatch | 9 months ago

CVS Health: Earnings Beat Ignites Stock Rally

Shares of CVS Health Corporation NYSE: CVS experienced a jolt, rising over 15% on February 12, 2025, as the market responded to the release of its fourth-quarter 2024 earnings report. CVS Health's stock price increase comes after a period of decline, causing investors to question whether this is a temporary upswing or a sign of a genuine turnaround.

Marketbeat | 9 months ago

These Analysts Boost Their Forecasts On CVS Health Following Upbeat Earnings

CVS Health Corp CVS reported upbeat earnings for its fourth quarter on Wednesday.

Benzinga | 9 months ago

CVS Health Jumps On Q4 Earnings Beat, But Downgrading To Hold

Despite a >10% rise in CVS Health's stock price from my initial BUY recommendation, CVS Health is downgraded to Hold due to substantial political risks and declining cash flow. CVS faces significant challenges, including DOJ lawsuits, potential business separation, political scrutiny, and declining cash flow, impacting its turnaround prospects. CVS reported strong Q4 sales and new leadership from the new CEO David Joyner may bode well for shareholders.

Seekingalpha | 9 months ago

S&P 500 Gains and Losses Today: CVS Stock Jumps as Pharmacy Segment Delivers Growth

Major U.S. equities indexes were mixed on Wednesday as the latest Consumer Price Index (CPI) data showed an unexpected uptick in inflation during January.

Investopedia | 9 months ago

CVS CEO defends pharmacy middlemen, accuses drugmakers of 'monopolistic' practices

CVS Health CEO David Joyner defended controversial pharmacy middlemen, who are widely accused of inflating prescription medication prices, and instead accused manufacturers of "monopolistic" practices that keep drug costs high in the U.S. Joyner, who stepped into the role in October, spent much of his opening remarks on the company's fourth-quarter earnings call discussing so-called pharmacy benefit managers, or PBMs.

Cnbc | 9 months ago

CVS shares move higher on upbeat Q4 report

CVS Health Corp (NYSE:CVS)'s shares surged more than 15% after the pharmacy chain posted positive financial results for the fourth quarter. Adjusted earnings per share of $1.19 on revenue of $97.71 billion topped analyst expectations of EPS of $0.91 on revenue of $96.89 billion.

Proactiveinvestors | 9 months ago